IMPACT BIOMEDICINES
Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis and polycythemia vera.
IMPACT BIOMEDICINES
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.impactbiomedicines.com
Total Employee:
5001+
Status:
Active
Contact:
858-221-0950
Total Funding:
112 M USD
Technology used in webpage:
Starfield Technologies Proofpoint CSC Global DNS
Similar Organizations
CorVent Medical
CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care.
Options MD
Options MD helps patients with treatment-resistant mental illnesses access better-performing treatments, faster.
Sirenas Marine Discovery
A Biomedical research organization
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
University Ambulatory Surgery Center
UASC focuses on providing the highest level of care and communication to our patient, physician specialists and their staff.
Current Advisors List
Board_member
Current Employees Featured
Catriona Jamieson Interim Chief Medical Officer and Co-Founder @ Impact Biomedicines
Interim Chief Medical Officer and Co-Founder
Charles McDermott President and Chief Business Officer @ Impact Biomedicines
President and Chief Business Officer
2017-08-01
Founder
Investors List
Oberland Capital
Oberland Capital investment in Debt Financing - Impact Biomedicines
Medicxi
Medicxi investment in Series A - Impact Biomedicines
Official Site Inspections
http://www.impactbiomedicines.com
- Host name: 165.160.15.20
- IP address: 165.160.15.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Impact Biomedicines"
IBO - Overview
5 days ago Impact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare. …See details»
Impact Biomedicines - Crunchbase Company Profile
Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around …See details»
About - Impact Biomedical, Inc.
About Us Leading Innovations in Global Human Health Impact Biomedical discovers, validates, and patents cutting-edge science and technologies, transforming them into innovative human health and wellness solutions. …See details»
Impact Biomedicines 2025 Company Profile: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for Impact Biomedicines. Use the PitchBook Platform to explore the full profile.See details»
Impact Biomedicines, Inc. - LinkedIn
Head of R&D, Vibrant Biomedicines; Special Advisor, F Prime Capital;| Vaccines & Biologics | Global R&D Leader | P&L | Board Director | Pharma |…See details»
Impact Biomedicines, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Impact Biomedicines, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Impact Biomedicines Company Profile - Office Locations ... - Craft
See insights on Impact Biomedicines including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Organization | Impact Biomedicines
Impact Biomedicines Report issue For profit Phase 1 Founded: San Diego CA United States (2016) Status: Acquired by Celgene (2018) → now Bristol-Myers Squibb (2019) Organization …See details»
Impact Biomedicines - Ownership and Business Overview - Mergr
Jan 7, 2018 Impact Biomedicines, Inc. is a developer of life changing treatments for patients with complex cancers. Impact Biomedicines was founded in 2016 and is based in San Diego, …See details»
Orphanet: IMPACT BIOMEDICINES, INC
Dear Orphanet User, Your opinion is essential in improving the services offered by Orphanet. Your contribution to this survey is also indispensable for our funding agencies. Please could …See details»
Impact Biomedical Inc - Drug pipelines, Patents, Clinical trials
Explore Impact Biomedical Inc with its drug pipeline, therapeutic area, technology platform, 11 news.See details»
Impact Biomedicines Company Profile | Management and
Impact Biomedicines Profile and History Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Companys pipeline is …See details»
Impact Biomedicines - Overview, News & Similar companies
View Impact Biomedicines (www.impactbiomedicines.com) location , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Impact Biomedicines - Products, Competitors, Financials, …
About Impact Biomedicines Impact Biomedicines is developing treatments for patients with complex cancers. The company's pipeline is centered around fedratinib, a potent and highly …See details»
Impact BioMedical Inc. (NYSE American: IBO) | LinkedIn
Impact BioMedical Inc. (NYSE American: IBO) Biotechnology Research Houston, Texas 311 followers Improving health outcomes in innovative ways based on nature's wisdom.See details»
Orphanet: Impact Biomedicines, Inc (a wholly-owned subsidiary of ...
Dear Orphanet User, Your opinion is essential in improving the services offered by Orphanet. Your contribution to this survey is also indispensable for our funding agencies. Please could …See details»
Impact BioMedical Inc. Introduces Leadership Team to Drive
Sep 23, 2024 Prior to joining DSS, Inc. as CEO in 2019, he had a successful career in commercial banking, serving in senior executive roles with major US and international banking …See details»
Impact Biomedicines Closes $90 Million Financing with Oberland …
Financing follows successful study of fedratinib in patients with myelofibrosis who were resistant or intolerant of ruxolitinib published in The Lancet Haematology SAN DIEGO, OCTOBER 26, …See details»
Impact Biomedicines Acquired By Celgene - Pharma's Almanac
Jan 16, 2018 Celgene to pay $1.1 billion upfront and up to $5.9 billion in milestone fees. In a move intended to diversify its portfolio, Celgene has agreed to acquire privately held San …See details»
The Impact of Resection Margins in Primary Resection of High
15 hours ago Background/Objectives: The World Health Organization’s (WHO) classification of tumors contains around 80 entities of soft tissue sarcomas (STSs). Currently, surgery is the …See details»